Citigroup’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCRX
Citigroup's PCRX Position: Q3 2026 in Review
Citigroup reduced its Pacira BioSciences (PCRX) stake by 17% in Q3 2026, selling an estimated $152K and leaving 29,600 shares worth $741K. The position accounts for ﹤0.01% of the portfolio, ranked #3516.
Citigroup first reported a position in PCRX in Q2 2013 and has held it in 54 quarters since. The position peaked at $4.62M in Q2 2017. 255 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.
- Citigroup held 29,600 shares of Pacira BioSciences worth $741K as of Q3 2026.
- Citigroup sold 6,011 Pacira BioSciences shares in Q3 2026, an estimated $152K.
- Pacira BioSciences made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3516 holding.
- Citigroup first reported a position in Pacira BioSciences in Q2 2013 and has held it in 54 quarters since.
- Citigroup's Pacira BioSciences position peaked at $4.62M in Q2 2017.
- 255 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.